Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing